Gujarat Themis Biosyn has raised Rs 585 crore through the allotment of Non-Convertible Debentures (NCDs) on private placement basis. The company is utilizing the NCDs proceeds inter alia for investing in its wholly subsidiary in Japan to finance the acquisition of MicroBiopharm Japan Co., and general corporate purpose. The Committee of the Board of Directors of the Company at its meeting held on September 16, 2026, has allotted the same.
Gujarat Themis Biosyn is a biotech and synthetic product manufacturing company.
